An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment With ACH-0144471 in Patients Who Completed Clinical Study ACH471-100
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
At a glance
- Drugs ACH 4471 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Achillion Pharmaceuticals
- 22 Feb 2018 According to an Achillion Pharmaceuticals media release, interim data from this study is expected in fourth quarter 2018.
- 29 Jun 2017 Status changed from not yet recruiting to recruiting.
- 12 Jun 2017 New trial record